NCT00562523View on ClinicalTrials.gov

Sorafenib/Docetaxel Dose Escalation Trial

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks

Trial Locations (2)

33612

Tampa

19111-2497

Philadelphia

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Bayer

INDUSTRY